相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
Yacine Bareche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death
Wei-Hsun Hsu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Intratumoral Heterogeneity: More Than Just Mutations
Kunihiko Hinohara et al.
TRENDS IN CELL BIOLOGY (2019)
Genetic and transcriptional evolution alters cancer cell line drug response
Uri Ben-David et al.
NATURE (2018)
Refining Early Antitumoral Drug Development
Alberto Ocana et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors
Hani M. Babiker et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
Alberto Ocana et al.
ONCOTARGET (2017)
Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells
Jarmila Herudkova et al.
NEOPLASIA (2017)
Conformational Change of Human Checkpoint Kinase 1 (Chk1) Induced by DNA Damage
Xiangzi Han et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Molecular Pathways: Targeting ATR in Cancer Therapy
Larry M. Karnitz et al.
CLINICAL CANCER RESEARCH (2015)
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Raymond Pagliarini et al.
EMBO REPORTS (2015)
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design
Andrew J. Massey et al.
ONCOTARGET (2015)
Collateral Lethality: A New Therapeutic Strategy in Oncology
Florian L. Muller et al.
TRENDS IN CANCER (2015)
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
J. C. Montero et al.
ONCOGENE (2014)
The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design
Ruth Thompson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
Debbie Saslow et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Preclinical development of molecular-targeted agents for cancer
Alberto Ocana et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Yun Dai et al.
CLINICAL CANCER RESEARCH (2010)
Preclinical versus clinical drug combination studies
Ting-Chao Chou
LEUKEMIA & LYMPHOMA (2008)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
MD Pegram et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
